What To Do When Free Speech No Longer Pays The Bills?
Antitrust and Constitutional law scholars, you're up!
Antitrust and Constitutional law scholars, you're up!
Antitrust division out there projecting strength.
Put away the guesswork—Lexis® Verdict & Settlement Analyzer helps legal professionals assess case potential with confidence by using data-driven insights from the industry’s largest collection of verdicts and settlements.
From the Federal Trade Commission to the literary ambitions of two sitting senators, the pressure is building from many directions.
Martin Shkreli, former company thwarted generic competition against toxoplasmosis drug, FTC says.
The only way to stop him is through extralegal means.
The Federal Trade Commission had accused Illumina of seeking to monopolize the market for next-generation sequencing in its effort to acquire Pacific Biosciences, originally announced in November 2018.
Takeaways from a Legalweek panel on evolving malpractice risks.
Federal regulators said they would seek to block the acquisition deal amid concerns that Illumina was seeking to eliminate PacBio as a competitor in the next-generation sequencing space.
Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing.
It's been a long time coming.
This is (potentially) awful.
Legal teams ask a practical question. If large language models are so capable, why does legal AI still depend on curated content, and why does surfacing that content matter so much?
What can an employer (legally) do to avoid employees leaving in droves for greener pastures?
Does using non-compete agreements to restrict the supply of viable employees violate the Sherman Act?
No merger for you!
There is an answer to why flying is the worst: the lawyers.
There's a lot to like about antitrust practice, including the sheer diversity of this area.